BioSpace News Archive

Alpine Immune Sciences, Inc. announced that the Company presented new preclinical data from a study of povetacicept in a murine experimental autoimmune myasthenia gravis (EAMG) model during the 148th Annual American Neurological Association (ANA) Meeting in Philadelphia, PA.

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence, announced that it has successfully completed enrollment in its first-in-man study of the UroActive™ System, the first smart automated artificial urinary sphincter to treat SUI.

MY01, Inc., a pioneering company dedicated to revolutionizing the diagnosis of compartment syndrome, announced it has achieved a milestone of serving 1000 patients at risk for this severe complication.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Raphael Bosse, MD, PhD has joined the statewide practice.

Dewpoint Therapeutics and Chemify today announced a partnership to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.

Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, today launched the Tapestri® Genome Editing Solution.

Protaryx Medical, a pioneer in medical device innovation, today announced the appointment of David Mester, MBA as its new chief executive officer (CEO).

Ferring Pharmaceuticals announced the first patient in the United States with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer was dosed with the commercially available intravesical gene therapy ADSTILADRIN® as part of the ADSTILADRIN Early Experience Program announced earlier this year.

FibroBiologics, a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the dedication of its cutting-edge laboratory facility as the Newlin-Linscomb Lab for Cell Therapeutics, within the University of Houston Innovation Center.

Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that analysis performed by Mass General Hospital led by Kyle Staller, M.D., has been accepted for presentation at the upcoming ACG 2023 Scientific Meeting in Vancouver on October 24, 2023.